Serum Ca 15-3: A Useful Tumor Marker in the Prognostication of Locally Advanced Breast Cancer

  • Mohd Rafey
  • Kafil Akhtar
  • Atia Zakaur Rab
  • Shahid Ali Siddiqui
Keywords: LABC, CA 15-3, Serum Marker.


Locally advanced breast cancer (LABC) continues to be a common presentation of breast cancer worldwide. Various serum markers have been studied to know the behaviour, metastasis and prognosis of breast cancer without going through any invasive procedure. CA 15-3 measures the protein product of the MUC 1 gene and is the most commonly used serum marker in breast cancer. The main use of serum CA 15-3 is monitoring therapy response and elevated levels are associated with metastatic disease and in non-metastatic patients, it is associated with poor prognosis. The aim of the study was to know the role of serum CA 15-3 level in diagnosis, prognosis and therapy response in patients with locally advanced breast cancer and to assess its relationship with other variables like tumor size, microscopic grade, nodal burden and Ki-67 antigen expression. Serum CA 15-3 levels significantly decreased after neo-adjuvant chemotherapy and mastectomy and it remained elevated in patients with suspected or hidden metastasis. Serum CA 15-3 levels exhibited positive statistically significant correlation with tumor size. DOI: 10.21276/AWCH.1782


1. Giordiano SH. Update on locally advanced breast cancer. The Oncologist 2003; 8(6): 521-530.
2. Valero V, Buzdar AU, Hortobagyi GN. Locally advanced breast cancer. Oncologist 1996; 1(1): 8-17.
3. Di Gioia, Dresse M, Mayr D, Nagel D, Heinemann V, Stieber P. Serum Her-2 in combination with CA 15-3 as a parameter for prognosis in patients with early breast cancer. Clinica Chimica Acta 2014; 440:16-22.
4. Dhafir Al-azawi, Gabrielle K, Eddy M, Michael J, Niall OH. CA 15-3 is predictive of response and disease recurrence following treatment in locally advanced breast cancer. BMC Cancer 2006; 6:220-221.
5. Duffy MJ, Duggan C, Keane R, Hill DK, McDermott E, Crown J et al. High preoperative CA 15.3 concentrations predict adverse outcome in node negative breast cancer: Study of 600 patients with histologically confirmed breast cancer. Clin Chem 2004; 50(3): 559-563.
6. Gautam A, Verma S, Pantola C, Verma S. Utility of CA 15.3 as diagnostic and prognostic marker in breast cancer. IOSR-JDMS 2015; 14(2): 17-20.
7. Hiba QA, Mahdi NK, Al-Jowher MH. The value of CA 15.3 in diagnosis, prognosis and treatment response in women with breast cancer. JPMA 2013; 63:1138-1140.
8. Yingbo S, Xianfu S, Yaning He, Chaojun L, Hui L. Elevated levels of serum tumor markers CEA AND CA 15-3 are prognostic parameters for different molecular subtypes of breast cancer. Plos One 2015; 10(7): 1-11.
9. Sandri MT, Salvatici M, Botteri E, Passerini R, Zorzino L, Rotmensz N et al. Prognostic role of CA 15.3 in 7942 patients with operable breast cancer. Breast Cancer Res Treat 2012; 132: 317-326.
10. Adela S, Daniel H, Christoph G, Erich FS, Christoph S, Ingolf JB. The potential role of preoperative cancer antigen CA 15.3 in prognosis of breast cancer. Int J Gynaecol Obstet 2015; 27(3): 115-119.
11. San-Gang W, Zhen-Yu H, Hong-Yue R, Li-Chao Y, Jia-Yuan S, Feng-Yan L et al. Use of CEA and CA 15.3 to predict axillary lymph node metastasis in patient with breast cancer. J Cancer 2016; 7(1): 37-41.
12. Lee JS, Park S, Cho JH, Kim SI, Park JM, Park BW. Elevated levels of preoperative CA 15.3 and CEA serum levels have independently poor prognostic significance in breast cancer. Ann Oncol 2012; 2: 1-7.
Original Articles